Moderna's personalized mRNA vaccine halves the risk of melanoma returning within five years, boosting survival and showing low toxicity in a clinical trial. The vaccine trains the immune system to target tumor-specific proteins, offering new hope for high-risk skin cancer patients.
Posts tagged as “Oncology”
Daraxonrasib nearly doubles median survival for advanced pancreatic cancer patients and offers better quality of life compared to chemotherapy. The oral drug targets KRAS mutations and is moving toward expedited FDA approval.